Russell Investments Group Ltd. Purchases 142,796 Shares of Option Care Health, Inc. $OPCH

Key Points

• Russell Investments Group Ltd. increased its holdings in Option Care Health, Inc. by 125.3%, acquiring an additional 142,796 shares and bringing its total ownership to 256,776 shares, valued at approximately $8.97 million.
• Option Care Health reported $0.41 earnings per share (EPS) for the quarter, slightly exceeding analysts' expectations, with revenues of $1.42 billion, a 15.4% year-over-year increase.
• Analyst ratings for Option Care Health have improved, with UBS Group upgrading it to a "buy" rating and raising the target price from $38 to $40, reflecting positive sentiment among analysts.

Russell Investments Group Ltd. increased its position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 125.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 256,776 shares of the company's stock after acquiring an additional 142,796 shares during the quarter. Russell Investments Group Ltd. owned about 0.16% of Option Care Health worth $8,974,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Compass Wealth Management LLC increased its holdings in Option Care Health by 8.9% in the 1st quarter. Compass Wealth Management LLC now owns 166,078 shares of the company's stock worth $5,804,000 after acquiring an additional 13,600 shares during the last quarter. Bessemer Group Inc. increased its holdings in Option Care Health by 62.3% in the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after acquiring an additional 599 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Option Care Health by 1.4% in the 1st quarter. Principal Financial Group Inc. now owns 485,871 shares of the company's stock worth $16,981,000 after acquiring an additional 6,616 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Option Care Health by 25.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 8,274 shares of the company's stock valued at $289,000 after buying an additional 1,691 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Option Care Health by 307.1% during the 1st quarter. GAMMA Investing LLC now owns 3,192 shares of the company's stock valued at $112,000 after buying an additional 2,408 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company's stock.

Analyst Upgrades and Downgrades

OPCH has been the subject of a number of recent analyst reports. Barrington Research reaffirmed an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a report on Thursday, July 10th. UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and lifted their target price for the company from $38.00 to $40.00 in a report on Wednesday, April 30th. JMP Securities lifted their target price on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a report on Thursday, July 31st. Finally, Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a report on Thursday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $35.75.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average price of $27.15 per share, for a total transaction of $977,400.00. Following the transaction, the director owned 375,390 shares in the company, valued at $10,191,838.50. The trade was a 10.61% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction dated Thursday, August 21st. The shares were acquired at an average price of $27.51 per share, with a total value of $550,200.00. Following the transaction, the director owned 49,229 shares in the company, valued at approximately $1,354,289.79. The trade was a 68.43% increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.64% of the company's stock.

Option Care Health Price Performance

Shares of OPCH traded up $0.90 during trading hours on Friday, reaching $28.74. 2,369,675 shares of the company's stock traded hands, compared to its average volume of 1,937,741. The stock has a market cap of $4.66 billion, a PE ratio of 22.99, a price-to-earnings-growth ratio of 1.82 and a beta of 0.79. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. The firm's 50 day simple moving average is $29.92 and its 200-day simple moving average is $31.75. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.01. The firm had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The company's revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter last year, the company posted $0.30 EPS. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Equities analysts expect that Option Care Health, Inc. will post 1.22 EPS for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.